Unknown

Dataset Information

0

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.


ABSTRACT: TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are among the myeloid malignancies with the poorest prognosis. In this review, we analyze the prognosis of these two diseases, focussing particularly on the extent of the mono or biallelic mutation status of TP53 mutation, which is largely correlated with cytogenetic complexity. We discuss the possible/potential improvement in outcome based on recent results obtained with new drugs (especially eprenetapopt and magrolimab). We also focus on the impact of allogeneic hematopoietic stem cell transplantation (aHSCT) including post aHSCT treatment.

SUBMITTER: Loschi M 

PROVIDER: S-EPMC9496940 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

How I Treat <i>TP53</i>-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Loschi Michael M   Fenaux Pierre P   Cluzeau Thomas T  

Cancers 20220918 18


<i>TP53</i>-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are among the myeloid malignancies with the poorest prognosis. In this review, we analyze the prognosis of these two diseases, focussing particularly on the extent of the mono or biallelic mutation status of <i>TP53</i> mutation, which is largely correlated with cytogenetic complexity. We discuss the possible/potential improvement in outcome based on recent results obtained with new drugs (especially eprenetapop  ...[more]

Similar Datasets

| S-EPMC8471083 | biostudies-literature
| S-EPMC10136154 | biostudies-literature
| S-EPMC5217532 | biostudies-literature
| S-EPMC8913568 | biostudies-literature
| S-EPMC7603787 | biostudies-literature
| S-EPMC9627130 | biostudies-literature
| S-EPMC7271596 | biostudies-literature
| S-EPMC8507987 | biostudies-literature
| S-EPMC8099409 | biostudies-literature